Publications
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Posters
March 2023
2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Apitegromab in SMA (TOPAZ trial): Covariates of Multiple Efficacy Endpoints From 24 Month Data
March 2023
European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Congress
Safety and efficacy results of SRK-181 (a latent TGFβ1 inhibitor) from a phase 1 trial (DRAGON trial)
November 2022
American College of Toxicology Annual Meeting 2022
Selective Latent TGFβ1 Inhibitors Exhibits Improved Nonclinical Safety Profile